{
    "score": [
        0.625
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "financial contrast : mesoblast versus ionis pharmaceuticals ."
    ],
    "id": "321759.train",
    "article": [
        "mesoblast and ionis pharmaceuticals are both medical companies , but which is the superior stock ? we will contrast the two companies based on the strength of their valuation , earnings , analyst recommendations , risk , dividends , institutional ownership and profitability . institutional and insider ownership2 .9 % of mesoblast shares are held by institutional investors . comparatively , 91.4 % of ionis pharmaceuticals shares are held by institutional investors . 2.1 % of ionis pharmaceuticals shares are held by company insiders . strong institutional ownership is an indication that large money managers , hedge funds and endowments believe a stock will outperform the market over the long term . ",
        "earnings & valuationthis table compares mesoblast and ionis pharmaceuticals ' gross revenue , earnings per share and valuation . gross revenueprice/sales rationet incomeearnings per shareprice/earnings ratiomesoblast $ 2.41 million203 .26 - $ 76.81 million-7.33 ionis pharmaceuticals $ 346.62 million18 .34 - $ 86.55 million $ 0.15339.56 mesoblast has higher earnings , but lower revenue than ionis pharmaceuticals . mesoblast is trading at a lower price-to-earnings ratio than ionis pharmaceuticals , indicating that it is currently the more affordable of the two stocks . volatility and riskmesoblast has a beta of 2.68 , indicating that its stock price is 168 % more volatile than the s&p 500 . ",
        "comparatively , ionis pharmaceuticals has a beta of 2.85 , indicating that its stock price is 185 % more volatile than the s&p 500 . profitabilitythis table compares mesoblast and ionis pharmaceuticals ' net margins , return on equity and return on assets . net marginsreturn on equityreturn on assetsmesoblast-2,006.86 % -12.04 % -9.60 % ionis pharmaceuticals3 .46 % 7.50 % 1.58 % analyst ratingsthis is a summary of current ratings and price targets for mesoblast and ionis pharmaceuticals , as provided by marketbeat . com . sell ratingshold ratingsbuy ratingsstrong buy ratingsrating scoremesoblast02402 .67 ionis pharmaceuticals26602 .29 mesoblast currently has a consensus price target of $ 14.25 , suggesting a potential upside of 149.13 % . ",
        "ionis pharmaceuticals has a consensus price target of $ 50.38 , suggesting a potential downside of 1.07 % . given mesoblast 's stronger consensus rating and higher probable upside , analysts plainly believe mesoblast is more favorable than ionis pharmaceuticals . summaryionis pharmaceuticals beats mesoblast on 9 of the 13 factors compared between the two stocks . about mesoblastmesoblast limited is engaged in developing cell-based medicines . the company has leveraged its technology platform , which is based on specialized cells known as mesenchymal lineage adult stem cells , to establish a portfolio of late-stage product candidates . its allogeneic , off-the-shelf cell product candidates target advanced stages of diseases with high , unmet medical needs , including cardiovascular conditions , orthopedic disorders , immunologic and inflammatory disorders and oncologic/hematologic conditions . ",
        "about ionis pharmaceuticalsionis pharmaceuticals , inc. . is engaged in discovering and developing ribonucleic acid - targeted therapeutics . the company , using its drug discovery platform , has developed a pipeline of drugs for patients with unmet medical needs . the company 's segments include ionis core and akcea therapeutics . in the ionis core segment , the company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the company and its partners . the akcea therapeutics segment includes the operations of the company 's subsidiary , akcea therapeutics , inc. . . ",
        "akcea therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders . the company is developing volanesorsen to treat two severe and rare , genetically defined diseases , familial chylomicronemia and familial partial lipodystrophy . the company offers spinraza , a generation 2.0 + antisense drug .   "
    ]
}